Abstract |
The number of patients with end-stage renal disease ( ESRD) has risen dramatically over the last decade. There are 300,000 patients in the United States with ESRD who are receiving hemodialysis (HD), and the incidence is increasing at a rate of 6% to 8% per year. Bacteremia, a prerequisite for infective endocarditis (IE), occurs at a rate of 0.7 to 1.4 episodes per 100 patient-care months. Few other medical conditions, except for chemotherapy-induced neutropenia, immunosuppression, and intravenous drug abuse, are associated with higher rates of bacteremia. IE occurs in approximately 2% to 6% of patients receiving HD. The aim of this article is to review the pathogenesis, diagnosis, current therapeutic options, and determinants of prognosis of IE in patients receiving HD.
|
Authors | Suraj Maraj, Larry E Jacobs, Rajiv Maraj, Morris N Kotler |
Journal | The American journal of the medical sciences
(Am J Med Sci)
Vol. 327
Issue 5
Pg. 242-9
(May 2004)
ISSN: 0002-9629 [Print] United States |
PMID | 15166741
(Publication Type: Journal Article)
|
Topics |
- Bacteremia
(diagnosis, etiology, physiopathology, therapy)
- Echocardiography
- Endocarditis, Bacterial
(diagnosis, etiology, physiopathology, therapy)
- Humans
- Kidney Failure, Chronic
(complications, therapy)
- Prognosis
- Renal Dialysis
- Risk Factors
|